TradeStation

Get Cash Back and $0 Commissions
+ The Power of TradeStation

Verona Pharma Announces June 2025 Investor Conference Participation

Globe Newswire 21-May-2025 6:00 AM

LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will participate in fireside chats at the following conferences in June 2025:

Jefferies Global Healthcare Conference

Date: Wednesday, June 4, 2025

Time: 11:05 a.m. ET / 4:05 p.m. BST

Location: New York, NY

Goldman Sachs 46th Annual Global Healthcare Conference

Date: Monday, June 9, 2025

Time: 2:40 p.m. ET / 7:40 p.m. BST

Location: Miami, FL

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com.

For further information please contact:

  
Verona Pharma plcTel: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and CommunicationsIR@veronapharma.com
Argot Partners

US Investor Enquiries
Tel: +1-212-600-1902

verona@argotpartners.com
Ten Bridge Communications

International / US Media Enquiries
Tel: +1-781-316-4424

tbcverona@tenbridgecommunications.com
Wendy Ryan 

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre® (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

Image for Press Release 2102918

Image for Press Release 2102918

Primary Logo

Market Data Delayed 15 Minutes